Status:
COMPLETED
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
Lead Sponsor:
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Collaborating Sponsors:
Marcus Vinícius Guimarães de Lacerda
Mayla Gabriela Silva Borba
Conditions:
SARS-CoV Infection
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male and female participants aged over 18 years old
- Hospitalized
- presenting:
- respiratory rate higher than 24 breathing incursions per minute AND/OR
- heart rate higher than 125 beats per minute (in the absence of fever) AND/OR
- peripheral oxygen saturation lower than 90% in ambient air AND/OR
- shock (defined as mean arterial pressure less than 65 mmHg, requiring vasopressor or oliguria or lowering level of consciousness)
- Exclusion Criteria:
- • None.
Exclusion
Key Trial Info
Start Date :
March 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2020
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT04323527
Start Date
March 23 2020
End Date
June 7 2020
Last Update
August 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz
Manaus, Amazonas, Brazil, 69093-415